So, what is Multiple Myeloma?
Myeloma, also known as multiple myeloma, is a blood cancer arising from plasma cells. At any one time there are around 17,500 people living with myeloma in the UK. It accounts for 15 per cent of blood cancers, and two per cent of all cancers. Myeloma mainly affects those over the age of 65, however it has been diagnosed in people much younger.
What are plasma cells?
Plasma cells are a type of white blood cell made in the bone marrow. Bone marrow is the ‘spongy’ material found in the centre of the larger bones in the body and is where all blood cells are made.
Plasma cells form part of your immune system. Normal plasma cells produce antibodies, also called immunoglobulins, to help fight infection.
How does myeloma develop?
Myeloma develops when DNA is damaged during the development of a plasma cell. This abnormal cell then starts to multiply and spread within the bone marrow. The abnormal plasma cells release a large amount of a single type of antibody – known as paraprotein – which has no useful function.
Unlike many cancers, myeloma does not exist as a lump or tumour. Most of the medical problems related to myeloma are caused by the build-up of abnormal plasma cells in the bone marrow and the presence of the paraprotein in the body.
Myeloma affects multiple places in the body, which is why it is referred to sometimes as ‘multiple’ myeloma. Myeloma affects where bone marrow is normally active in an adult, such as in the bones of the spine, skull, pelvis, the rib cage, long bones of the arms and legs and the areas around the shoulders and hips.
What are the symptoms of myeloma?
The most common symptoms of myeloma include bone pain, recurring infection, kidney damage and fatigue. Read more about the symptoms and complications of myeloma.
Is myeloma treatable?
Yes. Treatment for myeloma can be very effective at controlling the disease, relieving its symptoms and complications, and prolonging life. Unfortunately, though, myeloma is currently an incurable (terminal) cancer.
Myeloma is a relapsing-remitting cancer. This means there are periods when the myeloma is causing symptoms and/or complications and needs to be treated, followed by periods of remission or plateau where the myeloma does not cause symptoms and does not require treatment. Find out more about the treatment of myeloma.
What are plasma cells?
Plasma cells are a type of white blood cell made in the bone marrow. Bone marrow is the ‘spongy’ material found in the centre of the larger bones in the body and is where all blood cells are made.
Plasma cells form part of your immune system. Normal plasma cells produce antibodies, also called immunoglobulins, to help fight infection.
How does myeloma develop?
Myeloma develops when DNA is damaged during the development of a plasma cell. This abnormal cell then starts to multiply and spread within the bone marrow. The abnormal plasma cells release a large amount of a single type of antibody – known as paraprotein – which has no useful function.
Unlike many cancers, myeloma does not exist as a lump or tumour. Most of the medical problems related to myeloma are caused by the build-up of abnormal plasma cells in the bone marrow and the presence of the paraprotein in the body.
Myeloma affects multiple places in the body, which is why it is referred to sometimes as ‘multiple’ myeloma. Myeloma affects where bone marrow is normally active in an adult, such as in the bones of the spine, skull, pelvis, the rib cage, long bones of the arms and legs and the areas around the shoulders and hips.
What are the symptoms of myeloma?
The most common symptoms of myeloma include bone pain, recurring infection, kidney damage and fatigue. Read more about the symptoms and complications of myeloma.
Is myeloma treatable?
Yes. Treatment for myeloma can be very effective at controlling the disease, relieving its symptoms and complications, and prolonging life. Unfortunately, though, myeloma is currently an incurable (terminal) cancer.
Myeloma is a relapsing-remitting cancer. This means there are periods when the myeloma is causing symptoms and/or complications and needs to be treated, followed by periods of remission or plateau where the myeloma does not cause symptoms and does not require treatment. Find out more about the treatment of myeloma.
What's the treatment?
Treatment for myeloma is almost always with a combination of drugs. It’s usually given over a number of weeks, which may or may not be followed by a rest period. This pattern constitutes one cycle of treatment, and a series of treatment cycles is referred to as a course of treatment.
Your doctor may refer to all of your treatment as “chemo” or “chemotherapy” to keep things simple. In fact, treatment combinations are usually made up of two or three different types of drugs which work well together. These can include chemotherapy drugs, steroids and other types of anti-myeloma drugs.
Here are some of the most commonly used initial treatment combinations:
Your doctor may refer to all of your treatment as “chemo” or “chemotherapy” to keep things simple. In fact, treatment combinations are usually made up of two or three different types of drugs which work well together. These can include chemotherapy drugs, steroids and other types of anti-myeloma drugs.
Here are some of the most commonly used initial treatment combinations:
- Bortezomib (Velcade®), thalidomide and dexamethasone (known as VTD)
- Bortezomib (Velcade®), cyclophosphamide and dexamethasone (known as VCD)
- Melphalan, prednisolone and thalidomide (known as MPT)
- Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
- There are different combinations available.
So what's your treatment, Davey?
From the above list, I'm taking the VTD combination which comprises Thalidomide & Dexamethasone tablets with Velcade injection on two week on/off cycles. Once this part of the treatment has completed I will move on to the high-dose therapy and stem cell transplant.
And then what?
Well, that's the rub - as a newly diagnosed multiple myeloma patient who can tolerate thalidomide, and who is eligible for a stem cell transplant there is currently no maintenance treatment provided by the NHS. Revlimid (lenalidomide) has been trialled, and results have shown to give patients almost double the remission time before first relapse. We are not only fundraising in the hope of being able to pay for a first year of Revlimid treatment, but we're also joining the campaign for Revlimid to become standard of care first line maintenance. Further information is available here: https://www.myeloma.org.uk/news/lenalidomide-maintenance-increases-remission-time-in-newly-diagnosed-myeloma-patients/